Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed amning

Janusmed amning – tocilizumab

Janusmed amning tillhandahåller generella rekommendationer om huruvida ett friskt fullgånget spädbarn kan ammas när modern använder olika läkemedel. Observera att prematura och/eller sjuka spädbarn alltid kräver särskilda överväganden. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed amning och för att göra sökningar klicka här.

Tillbaka till index
3 3
3 3

Tocilizumab Testmiljö

Tocilizumab

Klass : 3

Visa all info

Skriv ut

Kontakta oss

  1. Saito J, Yakuwa N, Takai C, Nakajima K, Kaneko K, Goto M et al. Tocilizumab concentrations in maternal serum and breast milk during breastfeeding and a safety assessment in infants: a case study. Rheumatology (Oxford). 2018

  2. Nakajima K, Watanabe O, Mochizuki M, Nakasone A, Ishizuka N, Murashima A. Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan. Mod Rheumatol. 2016;4:1-5.

  3. Saito J, Yakuwa N, Kaneko K, Takai C, Goto M, Nakajima K et al. Tocilizumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk and infant serum. Rheumatology (Oxford). 2019;58(8):1505-1507.

  4. Saito J, Yakuwa N, Kaneko K, Nakajima K, Takai C, Goto M et al. Clinical application of the dried milk spot method for measuring tocilizumab concentrations in the breast milk of patients with rheumatoid arthritis. Int J Rheum Dis. 2019;22(6):1130-1137.

  5. Moriyama M, Wada Y, Minamoto T, Kondo M, Honda M, Murakawa Y. Unexpectedly lower proportion of placental transferred tocilizumab relative to whole immunoglobulin G: a case report. Scand J Rheumatol. 2020;49(2):165-166.

  6. Saito J, Yakuwa N, Kaneko K, Goto M, Kawasaki H, Hamamachi Y et al. Tocilizumab drug levels during pregnancy and lactation: A woman who discontinued tocilizumab therapy until the end of the first trimester and resumed it after birth. Obstet Med. 2021;14(4):260-262.

  1. Saito J, Yakuwa N, Takai C, Nakajima K, Kaneko K, Goto M et al. Tocilizumab concentrations in maternal serum and breast milk during breastfeeding and a safety assessment in infants: a case study. Rheumatology (Oxford). 2018
  2. Nakajima K, Watanabe O, Mochizuki M, Nakasone A, Ishizuka N, Murashima A. Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan. Mod Rheumatol. 2016;4:1-5.
  3. Saito J, Yakuwa N, Kaneko K, Takai C, Goto M, Nakajima K et al. Tocilizumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk and infant serum. Rheumatology (Oxford). 2019;58(8):1505-1507.
  4. Saito J, Yakuwa N, Kaneko K, Nakajima K, Takai C, Goto M et al. Clinical application of the dried milk spot method for measuring tocilizumab concentrations in the breast milk of patients with rheumatoid arthritis. Int J Rheum Dis. 2019;22(6):1130-1137.
  5. Moriyama M, Wada Y, Minamoto T, Kondo M, Honda M, Murakawa Y. Unexpectedly lower proportion of placental transferred tocilizumab relative to whole immunoglobulin G: a case report. Scand J Rheumatol. 2020;49(2):165-166.
  6. Saito J, Yakuwa N, Kaneko K, Goto M, Kawasaki H, Hamamachi Y et al. Tocilizumab drug levels during pregnancy and lactation: A woman who discontinued tocilizumab therapy until the end of the first trimester and resumed it after birth. Obstet Med. 2021;14(4):260-262.

Innehållet senast uppdaterat 11/7/2024